Premium
Systematic review of randomized controlled trials on antibiotic treatment for osteomyelitis in diabetes
Author(s) -
Xing K.,
Huang G.,
Hua S.,
Xu G.,
Li M.
Publication year - 2019
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.13935
Subject(s) - medicine , jadad scale , randomized controlled trial , blinding , cochrane library , antibiotics , medline , osteomyelitis , ertapenem , adverse effect , diabetes mellitus , intensive care medicine , surgery , antibiotic resistance , meropenem , political science , law , microbiology and biotechnology , biology , endocrinology
Aim To evaluate the efficacy of antibiotic therapy in osteomyelitis treatment among people with diabetes. Methods A systematic search of PubMed, EMBASE , AMED , Web of Science, the WHO trial registry, Cochrane library databases, and ClinicalTrials.gov, in addition to hand‐searching, was undertaken in July 2018. Two reviewers independently extracted data. The studies’ methodological quality was assessed using the modified Jadad scale. Descriptive analysis was performed. Results Seven randomized controlled trials, with 393 participants in total, were included. The antibiotic regimens, treatments and follow‐up durations varied among the trials. The total scores showed that the overall methodological quality of the seven studies was high, despite two studies showing some flaws in double‐blinding and withdrawals/drop‐outs. Of four studies comparing different antibiotic regimens, three implied a similar remission effect, while one implied that ertapenem ± vancomycin treatment showed a higher remission rate than tigecycline treatment; this conclusion was not robust because of low power and small sample size. In the other three studies, which included two different doses of ciprofloxacin, an antibiotics group and a conservative surgical group, and two durations of the same antibiotic strategy, no significant differences in remission were reported between the groups. No difference was observed in the analyses of microbiological outcomes, superinfections and relapse, except adverse events. Conclusions There is no definitive evidence supporting the superiority of any particular antibiotic agent, dose, or administration duration in the treatment of osteomyelitis in diabetes. As the included studies had some flaws and limitations, further research is necessary.